In cancers like breast cancer (BC), high p66Shc expression enhances chemotherapy sensitivity by promoting reactive oxygen species (ROS)‐mediated apoptosis, yet in other contexts, it drives tumour survival through pathways like PI3K/Akt, modulated by tumour type and microenvironment. Here, AKT1 is linked to neoplasm.